Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M J Ratain

Showing results (61-70 of 225) with videos related to

Pageof 23
Sort By:
Hematology/Oncology Clinics of North America|April 1, 1990
Hairy cell leukemia. Current managementL L Doane, M J Ratain, H M Golomb
Journal of the National Cancer Institute|November 16, 1994
Physician-determined patient risk of toxic effects: impact on enrollment and decision making in phase I cancer trialsR Mick, N Lane, C Daugherty, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1988
Skeletal complications in hairy cell leukemia: diagnosis and therapyB C Lembersky, M J Ratain, H M Golomb
Important Advances in Oncology|January 1, 1986
Sequential treatment of hairy cell leukemia: a new role for interferonH M Golomb, M J Ratain, J W Vardiman
Seminars in Oncology|September 1, 1986
The role of interferon in the treatment of hairy cell leukemiaM J Ratain, J W Vardiman, H M Golomb
Clinical Pharmacology and Therapeutics|November 19, 2013
Challenges in interpreting the evidence for genetic predictors of ototoxicityM J Ratain, N J Cox, T O Henderson
Clinical Pharmacology and Therapeutics|January 22, 2011
Merrill Jon Egorin, MD, 1948-2010M J Ratain, J M Collins, J H Doroshow
Cancer Chemotherapy and Pharmacology|January 1, 1996
Pharmacodynamic modeling of prolonged administration of etoposideH Minami, M J Ratain, Y Ando, et al.
Clinical Pharmacology and Therapeutics|March 21, 2014
Conventional dosing of anticancer agents: precisely wrong or just inaccurate?S Bins, M J Ratain, R H J Mathijssen
Clinical Pharmacology and Therapeutics|October 23, 2012
Models of excellence: improving oncology drug developmentM R Sharma, M L Maitland, M J Ratain
Pageof 23

Showing results (61-70 of 225) with videos related to

Sort By:
Pageof 23
Hematology/Oncology Clinics of North America|April 1, 1990
Hairy cell leukemia. Current managementL L Doane, M J Ratain, H M Golomb
Journal of the National Cancer Institute|November 16, 1994
Physician-determined patient risk of toxic effects: impact on enrollment and decision making in phase I cancer trialsR Mick, N Lane, C Daugherty, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1988
Skeletal complications in hairy cell leukemia: diagnosis and therapyB C Lembersky, M J Ratain, H M Golomb
Important Advances in Oncology|January 1, 1986
Sequential treatment of hairy cell leukemia: a new role for interferonH M Golomb, M J Ratain, J W Vardiman
Seminars in Oncology|September 1, 1986
The role of interferon in the treatment of hairy cell leukemiaM J Ratain, J W Vardiman, H M Golomb
Clinical Pharmacology and Therapeutics|November 19, 2013
Challenges in interpreting the evidence for genetic predictors of ototoxicityM J Ratain, N J Cox, T O Henderson
Clinical Pharmacology and Therapeutics|January 22, 2011
Merrill Jon Egorin, MD, 1948-2010M J Ratain, J M Collins, J H Doroshow
Cancer Chemotherapy and Pharmacology|January 1, 1996
Pharmacodynamic modeling of prolonged administration of etoposideH Minami, M J Ratain, Y Ando, et al.
Clinical Pharmacology and Therapeutics|March 21, 2014
Conventional dosing of anticancer agents: precisely wrong or just inaccurate?S Bins, M J Ratain, R H J Mathijssen
Clinical Pharmacology and Therapeutics|October 23, 2012
Models of excellence: improving oncology drug developmentM R Sharma, M L Maitland, M J Ratain
Pageof 23